Aldeyra verlängert Cash-Runway bis 2029 nach 45,1 Millionen US-Dollar Barmitteln per 30. Juni 2026

Von Public Technologies
  • Aldeyra Therapeutics verlängert die operative Cash-Runway-Prognose bis 2029.
  • Grundlage: ausgewiesene Barmittel und Barmitteläquivalente von 45.1 Millionen per 30. Juni 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609290700BIZWIRE_USPR_____20260929_BW404066) on September 29, 2026, and is solely responsible for the information contained therein.